Omneity® Pellets
All-In-One Vitamin & Mineral Pellet
Pharmacokinetic study of osilodrostat and identification of mono-hydroxylated metabolite in equine plasma for the purpose of doping control.
Abstract: Osilodrostat is an inhibitor of 11-beta-hydroxylase (CYP11B) and is used for the treatment of Cushing's disease but also categorized as an anabolic agent. The use of osilodrostat is prohibited in horseracing and equestrian sports. To the best of our knowledge, this is the first metabolic study of osilodrostat in equine plasma. Methods: Potential metabolites of osilodrostat were identified by differential analysis using data acquired from pre- and post-administration plasma samples after protein precipitation with liquid chromatography electrospray ionization high-resolution mass spectrometry (LC/ESI-HRMS). [Correction added on 27 January 2023, after first online publication: In the preceding sentence, "C-HRMS" was changed to "LC/ESI-HRMS" in this version.] For quantification of osilodrostat, a strong cation exchange solid-phase extraction was employed, and the extracts were analyzed using LC/ESI-triple quadrupole tandem mass spectrometry (LC/ESI-QqQ-MS/MS) to establish its elimination profile. Such extracts were further analyzed using LC/ESI-HRMS to investigate the detectability of osilodrostat and its identified mono-hydroxylated metabolite over a 2-week sampling period. Results: Mono-hydroxylated osilodrostat was identified based on the differential analysis and mass spectrometric interpretations, and it was found to be the most abundant metabolite in plasma. Elimination profile of osilodrostat in plasma was successfully established over the 24-h post-administration period. Both osilodrostat and its mono-hydroxylated metabolite were detected up to the last sampling point at 2 weeks using HRMS, and osilodrostat could be confirmed up to 8-day post-administration with its reference material using HRMS as well. Conclusions: For doping control, screening of both the parent drug osilodrostat and its mono-hydroxylated metabolite in equine plasma would be recommended due to their extended detection windows of up to 2 weeks. Given the availability of reference material for potential confirmation in forensic samples, osilodrostat is considered the most appropriate monitoring target.
© 2024 John Wiley & Sons Ltd.
Publication Date: 2024-02-15 PubMed ID: 38355879DOI: 10.1002/rcm.9695Google Scholar: Lookup The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The article discusses a study on osilodrostat, a drug used in Cushing’s disease treatment, focusing on its pharmacokinetics and metabolism in horse plasma for doping control in horse racing and equestrian sports. The research was able to identify a metabolite of the drug, establish its elimination profile, and recommend monitoring for doping control.
Research Methodology
- The study used equine plasma samples taken before and after the administration of osilodrostat.
- A differential analysis was performed using Liquid Chromatography Electrospray Ionization High-Resolution Mass Spectrometry (LC/ESI-HRMS) to identify potential metabolites of osilodrostat.
- The drug quantification was achieved using a strong cation exchange solid-phase extraction, and the extracts were analyzed with LC/ESI-Triple Quadrupole Tandem Mass Spectrometry (LC/ESI-QqQ-MS/MS) to establish the drug’s elimination profile.
- Further analysis was completed to study the detectability of the drug and its identified metabolite over a sampling period of 2 weeks.
Study Results
- A mono-hydroxylated metabolite of osilodrostat was identified as the most abundant metabolite in plasma using differential analysis and mass spectrometric interpretations.
- The drug’s elimination profile was successfully established over a 24-hour post-administration period.
- Both the drug and its identified metabolite were detected up to the final sampling point at two weeks with Osilodrostat confirmed up to 8 days post-administration with its reference material using HRMS.
Conclusions and Recommendations
- In doping control, both osilodrostat and its mono-hydroxylated metabolite should be screened due to their extended detection periods of up to two weeks.
- Given the availability of reference material for confirmation in forensic samples, osilodrostat was recommended as the most appropriate monitoring target.
Cite This Article
APA
Ishii H, Ishikawa Y, Mizobe F, Nomura M, Yamanaka T, Tanabe S, Nagata SI, Yamada M, Leung GN.
(2024).
Pharmacokinetic study of osilodrostat and identification of mono-hydroxylated metabolite in equine plasma for the purpose of doping control.
Rapid Commun Mass Spectrom, 38(5), e9695.
https://doi.org/10.1002/rcm.9695 Publication
Researcher Affiliations
- Drug Analysis Department, Laboratory of Racing Chemistry, Utsunomiya, Japan.
- Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.
- Anti-Doping Section, Equine Department, Japan Racing Association, Tokyo, Japan.
- Anti-Doping Section, Equine Department, Japan Racing Association, Tokyo, Japan.
- Anti-Doping Section, Equine Department, Japan Racing Association, Tokyo, Japan.
- Clinical Veterinary Medicine Division, Equine Research Institute, Shimotsuke, Japan.
- Clinical Veterinary Medicine Division, Equine Research Institute, Shimotsuke, Japan.
- Drug Analysis Department, Laboratory of Racing Chemistry, Utsunomiya, Japan.
- Drug Analysis Department, Laboratory of Racing Chemistry, Utsunomiya, Japan.
- Laboratory of Racing Chemistry, Utsunomiya, Japan.
MeSH Terms
- Animals
- Horses
- Doping in Sports / prevention & control
- Tandem Mass Spectrometry / methods
- Spectrometry, Mass, Electrospray Ionization / methods
- Chromatography, Liquid / methods
- Imidazoles
- Pyridines
Grant Funding
- Japan Racing Association (JRA)
References
This article includes 23 references
- European Medicines Agency. Assessment report Isturisa. .
- Duggan S. Osilodrostat: First approval. Drugs 2020;80(5):495-500.
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2022. .
- Fédération Équestre Internationale. 2023 Equine Prohibited Substances List. .
- International Federation of Horseracing Authorities. International Agreement on Breeding, Racing And Wagering And Appendixes (2023 edition with updated signatories). .
- Li W, Luo S, Rebello S, Flarakos J, Tse FL. A semi-automated LC-MS/MS method for the determination of LCI699, a steroid 11beta-hydroxylase inhibitor, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2014;960:182-193.
- Li L, Vashisht K, Boisclair J. Osilodrostat (LCI699), a potent 11beta-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. Toxicol Appl Pharmacol 2015;286(3):224-233.
- Armani S, Ting L, Sauter N. Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults. Clin Drug Investig 2017;37(5):465-472.
- Balakirouchenane D, Vasseur A, Bonnet-Serrano F. LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing's syndrome. J Pharm Biomed Anal 2023;228:115316.
- Association of Official Racing Chemists. AORC Guidelines for the Minimum Criteria for Identification by Chromatography and Mass Spectrometry. .
- Ishii H, Leung GN, Yamashita S. Doping control analysis of GW1516 in equine plasma using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry. Rapid Commun Mass Spectrom 2020;34(23):e8920.
- Ishii H, Shibuya M, Leung GN. Metabolic study of GW1516 in equine urine using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry for doping control. Rapid Commun Mass Spectrom 2021;35(5):e9028.
- Ishii H, Shibuya M, Leung GN. Detection and longitudinal distribution of GW1516 and its metabolites in equine hair for doping control using liquid chromatography/high-resolution mass spectrometry. Rapid Commun Mass Spectrom 2021;35(8):e9050.
- Ishii H, Shibuya M, So YM. Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometer for the purpose of doping control. Drug Test Anal 2022;14(2):233-251.
- Ishii H, Shibuya M, So YM. Long-term monitoring of IOX4 in horse hair and its longitudinal distribution with segmental analysis using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometry for the purpose of doping control. Drug Test Anal 2022;14(7):1244-1254.
- Ohnuma K, Uchida T, Leung GN, Ueda T, Obara T, Ishii H. Establishment of a post-race biomarkers database and application of pathway analysis to identify potential biomarkers in post-race equine plasma. Drug Test Anal 2022;14(5):915-928.
- Ishii H, Leung GN, Yamashita S. Comprehensive metabolic study of nicotine in equine plasma and urine using liquid chromatography/high-resolution mass spectrometry for the identification of unique biomarkers for doping control. J Chromatogr B Analyt Technol Biomed Life Sci 2022;1190:123100.
- Ishii H, Leung GN, Yamashita S. Identification of potential biomarkers in urine and plasma after consumption of tobacco product in horses. Drug Test Anal 2022;14(5):902-914.
- Ishii H, Shibuya M, Leung GN. Additional studies on nicotine exposure in horses: Accurate quantification and elimination profiles of potential biomarkers in plasma and urine. Rapid Commun Mass Spectrom 2022;36(23):e9396.
- Ishii H, Shibuya M, Kusano K. Pharmacokinetic study of vadadustat and high-resolution mass spectrometric characterization of its novel metabolites in equines for the purpose of doping control. Crurrent Drug Metabolism 2022;23(10):850-865.
- Ishii H, Shibuya M, Kusano K. Generic approach for the discovery of drug metabolites in horses based on data-dependent acquisition by liquid chromatography high-resolution mass spectrometry and its applications to pharmacokinetic study of daprodustat. Anal Bioanal Chem 2022;414(28):8125-8142.
- Ishii H, Shibuya M, Kusano K. Segmental analysis and long-term monitoring of vadadustat in equine hair for the purpose of doping control. J Anal Toxicol 2023;47(7):623-631.
- Ishii H, Shibuya M, Kusano K. First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis. J Pharm Biomed Anal 2023;235:115600.
Citations
This article has been cited 1 times.- Ishii H, Shigematsu R, Takemoto S, Ishikawa Y, Mizobe F, Nomura M, Arima D, Kunii H, Yuasa R, Yamanaka T, Tanabe S, Nagata SI, Yamada M, Leung GN. Quantification of osilodrostat in horse urine using LC/ESI-HRMS to establish an elimination profile for doping control. Bioanalysis 2024;16(17-18):947-958.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
